文献速递血液净化与透析慢性肾脏病

钙敏感受体基因型与血液透析患者对西那卡塞治疗的反应

Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-06-19

本研究基于EVOLVE试验的1852例血液透析患者DNA样本,分析18个CASR单核苷酸多态性(SNP)与基线矿物质代谢指标、20周内变化及临床骨折风险的关系。结果显示部分SNP与基线甲状旁腺激素、骨碱性磷酸酶、血钙及FGF23存在 modest 关联,且rs9740与西那卡塞治疗中血钙下降相关,三个连锁不平衡SNP与骨折风险升高相关但被西那卡塞减弱。这些关联若被验证,可能解释不同 ancestry 人群CKD-矿物质骨异常及对钙模拟剂反应的差异。

要点

  • CASR SNP与基线PTH、骨碱性磷酸酶、血钙及FGF23存在 modest 关联,且存在 ancestry 差异。
  • rs9740与西那卡塞治疗中血钙下降相关,在EA和AfAn人群均显著。
  • 三个连锁不平衡SNP与骨折风险升高相关,但该风险被西那卡塞减弱(EA人群)。

核心结论

  • CASR SNP与血液透析患者矿物质代谢指标及骨折风险存在 modest 关联,部分关联受西那卡塞影响。
  • 这些关联若被验证,可能解释EA和AfAn人群CKD-矿物质骨异常及对钙模拟剂反应的差异。

研究设计与样本

  • EVOLVE试验的DNA样本分析,该试验随机比较西那卡塞与安慰剂。
  • 3883例随机患者中1919例(49%)同意DNA采集,1852例成功进行18个CASR SNP基因分型。
  • EA人群1067例,AfAn人群405例,分别评估。

主要发现

  • EA人群中,CASR SNP次要等位基因与基线PTH和骨碱性磷酸酶升高 modest 关联(所有P≤0.03),AfAn人群未观察到此关联。
  • AfAn人群中,CASR SNP次要等位基因与基线血钙和FGF23降低 modest 关联(P=0.04),EA人群未观察到此关联。
  • EA人群中,两个SNP的次要等位基因与基线至20周PTH降低百分比减少相关(P<0.04),且不受西那卡塞影响。
  • EA和AfAn人群中,rs9740均与西那卡塞治疗时血钙降低相关(EA和AfAn P≤0.03)。
  • EA人群中,三个高度连锁不平衡SNP与临床骨折风险升高相关,但该风险被西那卡塞减弱(P<0.04)。

临床怎么用

  • CASR基因型可能有助于识别对西那卡塞生化反应不同的血液透析患者,尤其是血钙变化和骨折风险。
  • 目前证据尚不足以推荐常规基因检测指导西那卡塞用药。

局限性

  • 仅49%的随机患者同意DNA采集,可能存在选择偏倚。
  • 关联强度 modest,需独立验证。
  • 研究仅纳入EA和AfAn人群,其他 ancestry 人群结果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We tested the hypothesis that single nucleotide polymorphisms (SNPs) in the calcium-sensing receptor (CASR) alter the response to the calcimimetic cinacalcet. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed DNA samples in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial, a randomized trial comparing cinacalcet to placebo on a background of usual care. Of the 3883 patients randomized, 1919 (49%) consented to DNA collection, and samples from 1852 participants were genotyped for 18 CASR polymorphisms. The European ancestry (EA; n=1067) and African ancestry (AfAn; n=405) groups were assessed separately. SNPs in CASR were tested for their association with biochemical measures of mineral metabolism at baseline, percent change from baseline to 20 weeks, and risk of clinical fracture as dependent variables. RESULTS: There were modest associations of CASR SNPs with increased baseline serum parathyroid hormone and bone alkaline phosphatase primarily with the minor allele in the EA group (all P≤0.03), but not in the AfAn sample. In contrast, there was a modest association of decreased baseline serum calcium and FGF23 with CASR SNPs (P=0.04) primarily with the minor allele in the AfAn but not in the EA sample. The minor allele of two SNPs was associated with decreased percent reduction in parathyroid hormone from baseline to 20 weeks in the EA population (P<0.04) and this was not altered with cinacalcet. In both EA and AfAn, the same SNP (rs9740) was associated with decreased calcium with cinacalcet treatment (EA and AfAn P≤0.03). Three SNPs in high linkage disequilibrium were associated with a higher risk of clinical fracture that was attenuated by cinacalcet treatment in the EA sample (P<0.04). CONCLUSIONS: These modest associations, if validated, may provide explanations for differences in CKD-mineral bone disorder observed in EA and AfAn populations, and for differential biochemical responses to calcimimetics.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Moe SM, Wetherill L, Decker BS, et al. Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Clin J Am Soc Nephrol. 2017. PMID: 28630081. doi:10.2215/CJN.11141016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。